about
Identification of ALK as a major familial neuroblastoma predisposition geneGenome analysis and gene expression profiling of neuroblastoma and ganglioneuroblastoma reveal differences between neuroblastic and Schwannian stromal cells.PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma.Familial neuroblastoma: a complex heritable disease.Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastomaNew therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.Nanocarrier-mediated targeting of tumor and tumor vascular cells improves uptake and penetration of drugs into neuroblastoma.A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: Anti-angiogenic and anti-tumor effects.Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion.Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis.sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib.Evidence of epidermal growth factor receptor expression in uveal melanoma: inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity.Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma.Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis.Quiescent hepatic stellate cells functionally contribute to the hepatic innate immune response via TLR3.A new fluorescence-based optical imaging method to non-invasively monitor hepatic myofibroblasts in vivoCombined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A.Enhancement of Tumor Homing by Chemotherapy-Loaded NanoparticlesGenetic Predisposition to Familial Neuroblastoma: Identification of Two Novel Genomic Regions at 2p and 12pPHOX2B mutations and genetic predisposition to neuroblastomaWeak linkage at 4p16 to predisposition for human neuroblastomaOligogenic inheritance in neuroblastomaTargeting Macrophages as a Potential Therapeutic Intervention: Impact on Inflammatory Diseases and CancerRestriction fragment length polymorphism analysis reveals different allele frequency and a linkage disequilibrium at locus D1S94 in neuroblastoma patientsPeculiar allelotype associated with susceptibility to neuroblastomaMYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 childrenN-myc amplification and cell proliferation rate in human neuroblastomaConcomitant DDX1 and MYCN gain in neuroblastomaOvercoming Biological Barriers in Neuroblastoma Therapy: The Vascular Targeting Approach with Liposomal Drug NanocarriersCoated cationic lipid-nanoparticles entrapping miR-660 inhibit tumor growth in patient-derived xenografts lung cancer modelsCombined Replenishment of miR-34a and let-7b by Targeted Nanoparticles Inhibits Tumor Growth in Neuroblastoma Preclinical ModelsPotential Onco-Suppressive Role of miR122 and miR144 in Uveal Melanoma through ADAM10 and C-Met Inhibition
P50
Q24655923-292E2D8E-6EF6-40C2-8F04-C3C2637C1BE8Q33223772-32906E0A-BA67-4FB1-ABA9-B0817424EE5BQ33721880-7620983F-BA70-45C7-A8E4-E79DF6D03A41Q33721880-8E64AED5-AC15-4D65-BFB2-DF5886DC592DQ35184930-9B9BF6CB-F5AA-4123-9F16-B7A85927E468Q35623435-22E00122-ED51-4E93-B535-DB108D97556DQ36557133-63E0D096-368A-4DA0-8075-9804B1AC1E11Q38128317-04B5DB0C-0D7F-4D36-922A-2B3E076E6C8BQ38805799-CDCAC0AA-5201-4ACE-9DD4-D2D0F5DD84B8Q38843502-D037EE31-935E-41F7-9883-28461990A17AQ38868828-31E6C248-DDBC-4E32-A6B8-7B254B27CA4BQ38886708-E697B780-67D1-4093-8F48-3071FE5A162EQ38959374-BE8F5033-74DD-4382-8919-2E92FCB23798Q38973832-38AFA258-8186-4A75-AD5A-0BE442197146Q39126650-00A618AA-0044-473F-AA84-CF200E2EF512Q39646065-3CF674C5-6276-46D0-A7BB-43D7F609E4E3Q40112525-EFA45F92-8DAC-4C7B-AA5E-ECB8FA20853FQ41860012-FD5EED2A-3CFF-4BA1-84D2-C7A13DD471A3Q42578817-8CCD4723-86B4-4A34-957F-977EF4117E87Q43117144-77451565-779D-4937-9765-23790F288E09Q45864008-9B24E70C-E695-42C3-8297-482C96EC6DB1Q57183109-3B8FDA04-FAC9-4CD1-9645-BD7139154649Q58328226-30A49D40-F292-421A-ABDE-BC0E0503FE4FQ58328232-663A0C50-7E28-4B63-88B9-AB3DF404C1AEQ58328240-06A81C83-4FE1-4A0D-9F29-8A7937B77678Q60035816-29FEDCE9-8876-492F-9D80-84009BB8A180Q61051844-42538373-A155-4246-A25A-667CEADA65B9Q62036180-F5BF7796-4C3A-45B9-A32A-E91EE3A40175Q71722043-D00F211C-B9BD-4A3F-BBD3-9367A26BD568Q71975314-C09B1F04-DC3C-4A0C-9195-F5589522407EQ74016836-9CBC6D71-3830-4BEF-9F43-E2C93CD180D5Q80567570-2E88E67B-39EE-4E57-9717-100590D20616Q91301436-1E7B6A95-9E55-4F87-B708-94BC9DD547F3Q91830419-8FF2678B-8BED-4D4F-8EBE-1EBCA5C23DE2Q93171966-7540E9A6-C953-489D-90CD-11F41EFF0C06Q96227253-44A97119-8254-4794-9352-79136A6400BA
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Patrizia Perri
@ast
Patrizia Perri
@en
Patrizia Perri
@es
Patrizia Perri
@nl
Patrizia Perri
@sl
type
label
Patrizia Perri
@ast
Patrizia Perri
@en
Patrizia Perri
@es
Patrizia Perri
@nl
Patrizia Perri
@sl
prefLabel
Patrizia Perri
@ast
Patrizia Perri
@en
Patrizia Perri
@es
Patrizia Perri
@nl
Patrizia Perri
@sl
P106
P1153
7005327732
P21
P31
P496
0000-0003-2538-8278